Börse Express – Novamind completes acquisition in Arizona

TORONTO, ONTARIO / 18. January 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specializing in psychedelic medicine, discloses by reference to its Press release from December 23, 2021 (https://www.irw-press.com/de/news/novamind-unterzeichnet-finale-vereinbarung-zur-uebernahme-von-kliniken-in-arizona_63355.html) announced that it was acquiring (“Acquisition”) Arizona-based Foundations for Change, Inc. (“Foundations”). Foundations is a mental health practice specializing in ketamine-assisted psychotherapy.

“We are very pleased to welcome the Foundations team,” said Yaron Conforti, CEO and a director of Novamind. “For us at Novamind, the takeover is one great Opportunity to expand the reach of our clinic network and With ourin Model for innovative mental health care a new market in Arizona conquer.“

With the closing of the acquisition transaction, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, will assume the role of medical director at the Peoria and Phoenix clinic sites.

Mr. Edelman comments, “Our merger with Novamind is the right addition to our team and aligns with our mission to provide innovative and compassionate mental health care. I want our patienten, partners and the community for their continued support over the years. We look forward to continuing to care for more and more patientsen Integrate our team and operations into Novamind and benefit from the company’s deep expertise and excellent infrastructure.

In connection with the Acquisition, pursuant to the terms of various debt settlement agreements entered into with certain Foundations debt holders (the “Debt Holders”), the Company has acquired 441,261 common shares of the Company’s common stock (the “Shares”) at a designated price per share, the equivalent to $0.468 per share. The shares are subject to a statutory hold period expiring on May 18, 2022, in accordance with applicable Canadian securities laws and the articles of incorporation of the Canadian Securities Exchange. The enterprise hat the debt holder Besides that a total of $336,955 in cash paid. Please refer to the Company’s press release dated December 23, 2021 for further details regarding the Company’s acquisition transaction details remuneration to be paid.

See Also:  DBacks vs. Dodgers, MLB 2021: Schedule, TV, Where to watch LIVE

Over Novamind

Novamind is a leader in the mental health field, providing safe access to psychedelic medicines through a network of clinics and clinical research sites. Novamind is a provider of, through its network of integrative mental health clinics ketamingestützten Psychotherapies and other novel treatment methods. The company also operates a Full-Service contract research institute specializing in clinical trials and evidence-based research for psychedelic medicine. More information on how Novamind improves mental well-being and accompanies people throughout their healing process, see www.novamind.ca.

contact details

Yaron Conforti, CEO and Director

Tel: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications

E-mail: media@novamind.ca

Investor Relations

E-mail: IR@novamind.ca

Forward-Looking Statements

This press release contains forward-looking statements. All statements in this release that are not based on historical facts are forward-looking statements and involve risks and uncertainties. There can be no guarantee that such statements will prove to be true. Actual results and future events could differ materially from such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions to closing of the transaction, including the failure to obtain required third party and regulatory approvals, and other risks arising from Featured in the Company’s public announcements from time to time. As a result, there can be no guarantee that the transaction will be completed as proposed or at all. Readers are cautioned that forward-looking information is not reliable. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company will not update or publicly revise the forward-looking statements contained herein unless expressly required to do so by applicable law.

See Also:  Relive the Latest Super Bowl Halftime Shows | sports


The Company’s securities referred to in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”) or any state securities laws. Accordingly, the Company’s securities may not be offered or sold in the United States unless registered under the US Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the US Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any country in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor its regulatory service provider accepts responsibility for the adequacy or accuracy of this press release.

The source language (usually English) in which the original text is published is the official, authorized and legal version. This translation is included for better understanding. The German language version can be shortened or summarized. No responsibility or liability is accepted for the content, correctness, adequacy or accuracy of this translation. From the translator’s point of view, the report does not constitute a buy or sell recommendation! Please refer to the original English message www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company website!


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.